InsiderTrades.com logo
Who are Nvidia’s New Silent Partners?
From Weiss Ratings   |   Ad
Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.
I call these Nvidia’s “Silent Partners.”

GYRE Insider Trading

Insider Ownership Percentage: 2.92%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $324,024.00

Gyre Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Gyre Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Gyre Therapeutics Share Price & Price History

Current Price: $13.38
Price Change: ▲ Price Increase of +0.02 (0.15%)
As of 09/24/2024 03:08 PM ET

This chart shows the closing price history over time for GYRE up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
Biden's Executive Order, Dems Digital Money Legislation, First Step To
From Monetary Gold   |   Ad
Donald Trump once again sounded the alarm against Fed-controlled digital currencies (CBDCs). If these plans are implemented, it could mean the end of America as we know it.
This means you must act NOW before it's too late.

Gyre Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/28/2024Nassim UsmanDirectorSell3,452$12.00$41,424.001,636View SEC Filing Icon  
5/1/2024Nassim UsmanDirectorSell20,000$14.13$282,600.001,636View SEC Filing Icon  
See Full Table
The most serious warning of my career
From Porter & Company   |   Ad
With the 2024 election just weeks away, a new crisis is barrelling down on America… one that could cleave the financial world in two the moment the polls close. I predict they could see investment losses of 50% (or more) in the weeks following the presidential election.
Click here now to grab your seat now.

SEC Filings (Institutional Ownership Changes) for Gyre Therapeutics (NASDAQ:GYRE)

23.99% of Gyre Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at GYRE by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Gyre Therapeutics Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
8/14/2024Marshall Wace LLP10,720$0.13M0.0%-58.0%0.013%Search for SEC Filing on Google Icon
8/9/2024Renaissance Technologies LLC13,900$0.17M0.0%N/A0.016%Search for SEC Filing on Google Icon
8/9/2024WINTON GROUP Ltd18,467$0.22M0.0%N/A0.022%Search for SEC Filing on Google Icon
8/1/2024Rhumbline Advisers10,291$0.12M0.0%N/A0.012%Search for SEC Filing on Google Icon
7/26/2024Bank of New York Mellon Corp18,266$0.22M0.0%N/A0.021%Search for SEC Filing on Google Icon
5/10/2024Vanguard Group Inc.195,098$3.41M0.0%-1.5%0.228%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Gyre Therapeutics logo
Gyre Therapeutics, Inc., a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases. In addition, it advances a product pipeline in China, including Pirfenidone, for dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, as well as for diabetic kidney disease; and product candidates for acute-on-chronic liver failure, chronic obstructive pulmonary disease, and pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California.
Read More on Gyre Therapeutics

Today's Range

Now: $13.38
Low: $12.90
High: $13.59

50 Day Range

MA: $12.98
Low: $9.90
High: $15.71

52 Week Range

Now: $13.38
Low: $4.80
High: $30.40

Volume

44,754 shs

Average Volume

73,506 shs

Market Capitalization

$1.14 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.07

Who are the company insiders with the largest holdings of Gyre Therapeutics?

Gyre Therapeutics' top insider investors include:
  1. Nassim Usman (Director)
Learn More about top insider investors at Gyre Therapeutics.

Who are the major institutional investors of Gyre Therapeutics?

Gyre Therapeutics' top institutional shareholders include:
  1. WINTON GROUP Ltd — 0.02%
  2. Bank of New York Mellon Corp — 0.02%
  3. Renaissance Technologies LLC — 0.02%
  4. Marshall Wace LLP — 0.01%
  5. Rhumbline Advisers — 0.01%
Learn More about top institutional investors of Gyre Therapeutics stock.

Which major investors are selling Gyre Therapeutics stock?

In the last quarter, GYRE stock was sold by these institutional investors:
  1. Marshall Wace LLP

Which major investors are buying Gyre Therapeutics stock?

During the last quarter, GYRE stock was purchased by institutional investors including:
  1. WINTON GROUP Ltd
  2. Bank of New York Mellon Corp
  3. Renaissance Technologies LLC
  4. Rhumbline Advisers
Who are Nvidia’s New Silent Partners?
From Weiss Ratings   |   Ad
Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.
I call these Nvidia’s “Silent Partners.”